By Jonathan Cong, Aton Biotech
Published in: Outsourced Pharma, Aton Biotech video
Published on: September 16, 2024
Introduction to a video presentation. The successful development and approval of biosimilars hinge on the rigorous demonstration of their comparability to their reference biologics. This presentation outlines a comprehensive framework for conducting robust comparability studies that ensure biosimilars meet stringent standards for safety, efficacy, and quality.
Central to this framework is a deep understanding of regulatory expectations and guidelines. We delve into the pivotal role of comparability studies and discuss the key aspects that regulatory authorities scrutinize. Furthermore, we explore effective strategies for managing the complexities inherent in comparability studies, addressing critical considerations such as study design, analytical methods, and data interpretation. By implementing these strategies, stakeholders can contribute to the development of high-quality biosimilars that meet the needs of patients and healthcare providers worldwide while mitigating risks and enhancing the credibility of their biosimilar development programs.
